貨號(hào)：DHB88201

產(chǎn)品鏈接：http://www.atagenix.com/product_detail-75271.html

產(chǎn)品購(gòu)買聯(lián)系方式：027-65279366

產(chǎn)品介紹：Garadacimab (CSL312)是一流的全人IgG4單克隆抗體，靶向活化因子XII (FXIIa)。Garadacimab 具有用于遺傳性血管性水腫研究的潛力。

通用名：Garadacimab

純度：>95% by SDS-PAGE.

濃度：1mg/ml

Formulationicon：0.01M PBS, pH 7.4.

內(nèi)毒素：Please contact with the lab for this information.

別名：CSL312

靶點(diǎn);物種：Human F12

種類：Humanized

受體鑒定:IgG4-lambda

CAS: 2162134-62-3

存儲(chǔ)條件：Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

Store at +4°C short term (1-2 weeks).

Store at -20 °C 12 months.

Store at -80°C long term.

參考文獻(xiàn)：

Prophylactic use of an anti-activated factor XII monoclonal antibody, garadacimab, for patients with C1-esterase inhibitor-deficient hereditary angioedema: a randomised, double-blind, placebo-controlled, phase 2 trial. PMID: 35219377

Efficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention (VANGUARD): a global, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. PMID: 36868261

Treatment of hereditary angioedema-single or multiple pathways to the rescue. PMID: 36172291

A phase I, first-in-human, randomized dose-escalation study of anti-activated factor XII monoclonal antibody garadacimab. PMID: 34859955

Efficacy and Safety of Garadacimab in Combination with Standard of Care Treatment in Patients with Severe COVID-19. PMID: 37000214

Pharmacokinetic/pharmacodynamic modeling for dose selection for the first-in-human trial of the activated Factor XII inhibitor garadacimab (CSL312). PMID: 34811931

HDX-MS study on garadacimab binding to activated FXII reveals potential binding interfaces through differential solvent exposure. PMID: 36628468

Factor XII/XIIa inhibitors: Their discovery, development, and potential indications. PMID: 32883641

Fit-for-purpose validation of a drug-tolerant immunogenicity assay for a human mAb drug in animal safety studies. PMID: 36526009